RAR and RXR modulation in cancer and metabolic disease

Nature Reviews Drug Discovery

Volumn 6, Issue 10, 2007, Pages 793-810

  Altucci, Lucia ^a   Leibowitz, Mark D ^b   Ogilvie, Kathleen M ^c   de Lera, Angel R ^d   Gronemeyer, Hinrich ^e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b LIGAND PHARMACEUTICALS INC   (United States)

^c EXELIXIS INC   (United States)

^d UNIVERSITY OF VIGO   (Spain)

^e INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ALITRETINOIN; ALPHA2A INTERFERON; AMINOPHYLLINE; ANTINEOPLASTIC AGENT; BEXAROTENE; BORTEZOMIB; FENRETINIDE; GLITAZONE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; ISOTRETINOIN; LONAFARNIB; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA BLOCKING AGENT; RETINOIC ACID RECEPTOR ALPHA STIMULATING AGENT; RETINOIC ACID RECEPTOR BETA STIMULATING AGENT; RETINOIC ACID RECEPTOR GAMMA STIMULATING AGENT; RETINOIC ACID RECEPTOR MODULATOR; RETINOID; RETINOID DERIVATIVE; RETINOID X RECEPTOR BLOCKING AGENT; RETINOID X RECEPTOR MODULATOR; RETINOID X RECEPTOR STIMULATING AGENT; RITUXIMAB; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER INHIBITION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EPIGENETICS; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; LEUKEMOGENESIS; LIGHT DAMAGE; LYMPHOMA; METABOLIC DISORDER; MONOTHERAPY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SKIN DEFECT; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; DIABETES MELLITUS; HUMANS; LIGANDS; NEOPLASMS; OBESITY; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS;

EID: 34848834842     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2397     Document Type: Review

References (184)

1. Gronemeyer, H., Gustafsson, J. A. & Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nature Rev. Drug Discov. 3 950-964 (2004).
2. Smith, C. L & O'Malley. B. W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71 (2004).
3. Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N. & Noy, N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129, 723-733 (2007).
4. Stehlin-Gaon, C. et al. All-trans retinoic acid is a ligand for the orphan nuclear receptor RORβ. Nature Struct. Biol. 10, 820-825 (2003).
5. Miller, V. A. et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD 1069. J. Clin. Oncol. 15, 790-795 (1997).
6. Mark, M., Ghyselinck, N. B, & Chambon, P. Function of retinoid nuclear receptors: Lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu. Rev. Pharmacol. Toxicol. 46, 451-480 (2006).
7. Lengfelder, E., Saussele, S., Weisser, A., Buchner, T. & Hehlmann, R. Treatment concepts of acute promyelocytic leukemia. Crit. Rev. Oncol. Hematol. 56, 261-274 (2005).
8. Rego, E. M. & Pandolfi, P. P. Reciprocal products of chromosomal translocations in human cancer pathogenesis: Key players or innocent bystanders? Trends Mol. Med. 8, 396-405 (2002).
9. Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811-820 (2000).
10. Zeisig, B. B. et al. Recruitment of RXR by homotetrameric RARα fusion proteins is essential for transformation. Cancer Cell 12 36-51 (2007).
11. Zhu, J. et al. RXR is an essential component of the oncogenic PML/ RARA complex in vivo. Cancer Cell 12: 23-35 (2007).
12. Zhu. J. et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7, 143-153 (2005).
13. Kamashev, D., Vitoux, D. & De The, H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J. Exp. Med. 199, 1163-1174 (2004).
14. Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079-1082 (2002).
15. Lim, H. K., Bergmann, S. & Pandolfi, P. P. Cytoplasmic PML function in TGF-β signalling. Nature 431, 205-211 (2004).
16. de Stanchina, E. et al. PML is a direct p53 target that modulytes p53 effector functions. Mol. Cell 13, 523-535 (2004).
17. Bernardi, R. et al. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nature Cell Biol. 6, 665-672 (2004).
18. Insinga, A. et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 23, 1144-1154 (2004).
19. Altucci, L. et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature Med. 7, 680-686 (2001).
20. Clarke, N., Jimenez-Lara, A. M., Voltz, E. & Gronemeyer, H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 23, 3051-3060 (2004).
21. Hong, S. H., David, G., Wong, C. W. Dejean, A. & Privalsky, M. L. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 9028-9033 (1997).
22. Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811-814 (1998).
23. He, L. Z. et al. Distinct interactions of PML-RARα and PLZF - RARα with co- repressors determine differential responses to RA in APL. Nature Genet. 18, 126-135 (1998).
24. Grignani, F. et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815-818 (1998).
25. Ferrara. F. F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2-7 (2001).
26. Widschwendter, M. et al. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J. Natl Cancer Inst. 92, 826-832 (2000).
27. Ivanova, T. et al. Methylation and silencing of the retinoic acid receptor-β 2 gene in cervical cancer. BMC Cancer 2, 4 (2002).
28. Kuroki, T. et al. Allele loss and promoter hypermethylation of VHL, RAR-β, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res. 63, 3724-3728 (2003).
29. Mehrotra, J. et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin. Cancer Res. 10, 3104-3109 (2004).
30. Sirchia, S. M. et al. Endogenous reactivation of the RARβ2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 62, 2455-2461 (2002).
31. Yang, O. et al. 5-aza-2′-deoxycytidine induces retinoic acid receptor β 2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anticancer Res. 22, 2753-2756 (2002).
32. Suh, Y. A. et al. Loss of retinoic acid receptor β gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res. 62, 3945-3949 (2002).
33. Faria, T. N., Mendelsohn. C.. Chambon, P. & Gudas, L. J. The targeted disruption of both alleles of RARβ(2) in F9 cells results in the loss of retinoic acid-associated growth arrest. J. Biol. Chem. 274 26783-26788 (1999).
34. Berg, W J. et al. Up-regulation of retinoic acid receptor β expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-α-2a. Clin. Cancer Res. 5, 1671-1675 (1999).
35. Germain, P. et al. Rational design of RAR-selective ligands revealed by RARß crystal stucture. EMBO Rep. 5, 877-882 (2004).
36. Yin, W., Raffelsberger, W. & Gronemeyer, H. Retinoic acid determines life span of leukemic cells by inducing antagonistic apoptosis-regulatory programs. Int. J. Biochem. Cell Biol. 37 1696-1708 (2005).
37. Kim, P. K. et al. IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene 23, 1125-1135 (2004).
38. Kroger, A., Dallugge, A., Kirchhoff, S. & Hauser, H. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo. Oncogene 22, 1045-1056 (2003).
39. Wolf, S. et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int. J. Cancer 118, 1831-1835 (2005).
40. Frank, B, et al. Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. Carcinogenesis 26, 1975-1977 (2005).
41. Adams, J., Cuthbert-Heavens, D., Bass, S. & Knowles, M. A. Infrequent mutation of TRAIL receptor 2 [TRAlL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett. 220, 137-144 (2005).
42. Wang, S. & El-Deiry, W. S. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res. 64, 6666-6672 (2004).
43. Litwack, G. TRAIL (Vitamins and Hormones) Vol. 67 (Academic Press, San Diego, 2004).
44. Takeda, K. et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437-448 (2004).
45. Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169 (2002).
46. Altucci, L. et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res. 65, 8754-8765 (2005).
47. Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med. 11, 77-84 (2005).
48. Insinga. A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med. 11, 71-76 (2005).
49. Nesterov, A., Nikrad, M., Johnson, T. & Kraft, A. S. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-α-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 64, 3922-3927 (2004).
50. Wang. Y. et al. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5, 501-512 (2004).
51. Rottmann, S., Wang, Y., Nasoff, M., Deveraux. O. L. & Quon, K. C. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3β/FBW7 loss of function. Proc. Natl Acad. Sci. USA 102, 5195-15200 (2005).
52. Fenaux, P., Chomienne, C. & Degos, L. All-trans retinoic acid and chemotherapy in the treatment of acute-promyelocytic leukemia. Semin. Hematol. 38, 13-25 (2001).
53. Liu, X., Yue, P., Khuri, F. R. & Sun. S. Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 64, 5078-5083 (2004).
54. Wang, S. & El-Deiry, W. S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad. Sci. USA 100, 15095-15100 (2003).
55. Ganten, T. M. et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL Hepatology 42, 588-597 (2005).
56. Liu, M., Iavarone. A. & Freedman, L. P. Transcriptional activation of the human p2l (WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J. Biol. Chem. 271, 31723-31728 (1996).
57. Keedwell, R. G. et al. An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate-epithelium. Br. J. Cancer 91, 580-588 (2004).
58. Gui, C. Y., Ngo, L., Xu, W. S., Richon, V. M. & Marks. P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl Acad. Sci. USA 101, 1241-1246 (2004).
59. Greenhalgh, D. A., Welty. D. J., Player, A. & Yuspa, S. H. Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma. Proc. Natl Acad. Sci. USA 87, 643-647 (1990).
60. Leder, A., Kuo, A., Cardiff, R. D., Sinn, E. & Leder. P, v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl Acad. Sci. USA 87, 9178-9182 (1990).
61. Anzano, M. A. et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54, 4614-4617 (1994).
62. Huang, C. et al. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc. Natl. Acad. Sci. USA 94, 5826-5830 (1997).
63. Chen. J. Y. et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14, 1187-1197 (1995).
64. Fisher, G. J. et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 379, 335-339 (1996).
65. Wang, Z. Boudjelal, M., Kang, S., Voorhees, J. J. & Fisher, G. J. Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment. Nature Med. 5, 418-422 (1999).
66. Alttucci, L & Gronemeyer H. The promise of retinoids to fight against cancer. Nature Rev. Cancer 1, 181-193 (2001).
67. Soprano, D. R., Oin. P. & Soprano, K. J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 24, 201-221 (2004).
68. Herold, C. et al. Combined in vitro anti-tumoral action of tamoxifen and retinoic add derivatives in hepatoma cells. Int. J. Oncol. 20, 89-96 (2002).
69. Di Bisceglie, A. M., Osmack, P. & Brunt, E. M. Chemoprevention of hepatocellular carcinoma: Use of tamoxifen in an animal model of hepatocarcinogenesis. J. Lab. Clin. Med. 145, 134-138 (2005).
70. Vertuani, S. et al. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res. 63, 8006-80013 (2003).
71. Tsimberidou, A. M., Giles, F., Romaguera, J., Duvic, M. & Kurzrock, R. Activity of interfaron-α and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 100, 574-580 (2004).
72. Aass, N. et al. Randomized phase II/III trial of interferon α2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J. Clin. Oncol. 23, 4172-4178 (2005).
73. Baumann, L. et al. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 76, 69-73 (2005).
74. Aboulafla, D. M. et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: Results of a phase 2 multicenter clinical trial. Arch. Dermatol. 139, 178-186 (2003).
75. Recchia, F. et al. Phase II randomized study of interieukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. Anticancer Res. 25, 3149-3157 (2005).
76. Holmes, W. F., Dawson, M. I., Soprano, R. D. & Soprano, K. J. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J. Cell. Physiol. 185, 61-67 (2000).
77. Zhang, X. K. Targeting Nur77 translocation. Expert Opin. Ther. Targets 11, 69-79 (2007).
78. Decensi, A. et al. Fenretinide and risk reduction of second, breast cancer. Nature Clin. Pract. Oncol. 4, 64-65 (2007).
79. Chun, K. H., Benbrook. D. M., Berlin, K. D., Hong, W.K. & Lotan, R. The synthetic heteroarcitinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res. 63, 3826-3832 (2003).
80. Bayon, Y. et al. Inhibition of IκB kinase by a new class of retinoid-related anticancer agents that induce apoptosis. Mol. Cell. Biol. 23, 1061-1074 (2003).
81. Cincinelli, R. et al. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J. Med. Chem. 46, 909-912 (2003).
82. Calleja, C. et al. Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes. Genes Dev. 20, 1525-1538 (2006).
83. Benoit, G. R. et al. Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. Mol. Endocrinol. 15, 1154-1169 (2001).
84. Kempf, W. Kettelhack, N.. Duvic, M. & Burg, G. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am. 17, 1405-1419 (2003).
85. Zhang, C. & Duvic, M. Retinoids: Therapeutic-applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol. Ther. 16, 322-330 (2003).
86. McGinnis, K. S. et al. The addition of interferon γ to oral bexarotene therapy with photopheresis for Sezary syndrome. Arch. Dermatol. 141, 1176-1178 (2005).
87. Smit, J. V. et al. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J. Am. Acad. Dermatol. 51, 249-256 (2004).
88. Edelman, M. J. et al. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5774-5778 (2005).
89. Tyagi, P. Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: Results from the SPIRIT I and II trials. Clin. Lung Cancer 7, 17-19 (2005).
90. Crowe, D. L & Chandraratna, R. A. A retinoid X receptor (RXR -selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6, R546-R555 (2004).
91. Liby, K. T., Yore, M. M. & Sporn, M. B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature Rev. Cancer 7, 357-369 (2007).
92. Balasubramanian, S., Chandraratna, R. A. & Eckert, R. L. Suppression of human pancreatic cancer cell proliferation by AGN 194204, an RXR-selective retinoid. Carcinogenesis 25, 1377-1385 (2004).
93. Lippman, S. M., Sudbo, J. & Hong, W. K. Oral cancer prevention and the evolution of molecular-targeted drug development. J. Clin. Oncol. 23, 346-356 (2005).
94. Kojima, S., Okuno, M., Matsushima-Nishiwaki, R., Friedman, S. L & Moriwaki, H. Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). Int. J. Oncol. 24, 797-805 (2004).
95. Okuno, M. et al. Retinoids in cancer chemoprevention. Curr. Cancer Drug Targets 4, 285-298 (2004).
96. Serrano, D., Perego, E., Costa, A. & Decensi, A. Progress in chemoprevention of breast cancer. Crit. Rev. Oncol. Hematol. 49 109-117 (2004).
97. Decensi, A.. Serrano, D., Bonanni, B., Cazzaniga, M. & Guerrieri-Gonzaga, A. Breast cancer prevention trials using retinoids. J. Mammary Gland Biol. Neoplasia 8, 19-30 (2003).
98. Thacher, S. M., Vasudevan, J. & Chandraratna, R. A. Therapeutic applications for ligands of retinoid receptors. Curr. Pharm. Des. 6, 25-58 (2000).
99. +1- mice exposed to ultraviolet or ionizing radiation. Cancer Res. 64, 4385-4389 (2004).
100. Peris, K., Fargnoli, M. C. & Chimenti, S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N. Engl. J. Med. 341, 1767-1768 (1999).
101. Gottardis, M. M. et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand. Cancer Res. 56 5566-5570 (1996).
102. Lallemand-Breitenbach, V., Zhu, J., Kogan, S., Chen, Z. & de The, H. How patients have benefited from mouse models of acute promyelocytic leukaemia. Nature Rev. Cancer 5, 821-827 (2005).
103. Benoit, G. et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18, 7011-7018 (1999).
104. Zhac, O. et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia 18, 285-292 (2004).
105. Parrella, E. et al. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways, J. Biol. Chem. 279, 42026-42040 (2004).
106. Guillemin, M. C. et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J. Exp. Med. 196, 1373-1380 (2002).
107. Lippman, S. M., Lotan, R. & Schleuniger, U. Retinoid-interferon therapy of solid tumors. Int. J. Cancer 70, 481-483 (1997).
108. Kalvakolanu, D. V. The GRIMs: A new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev. 15, 169-194 (2004).
109. Um, S. J. et al. Antiproliferative effects of retinoic acid/ interferon in cervical carcinoma cell lines: Cooperative growth suppression of IRF-1 and p53. Int. J. Cancer 85, 416-423 (2000).
110. Liston, P. et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nature Cell Biol. 3, 128-133 (2001).
111. Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004).
112. Feinberg, A. P. & Tycko, B. The history of cancer epigenetics. Nature Rev. Cancer 4, 143-153 (2004).
113. Bachman, K. E. et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3, 89-95 (2003).
114. Marks, P. et al. Histone deacetylases and cancer: Causes and therapies. Nature Rev. Cancer 1, 194-202 (2001).
115. Warrell, R. P., Jr, He, L. Z., Richon, V., Calleja, E. & Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90, 1621-1625 (1998).
116. He, L. Z. et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108, 1321-1330 (2001).
117. Klisovic, M. I. et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML 1/ETO-positive leukemic cells. Leukemia 17, 350-358 (2003).
118. Altucci, L, Clarke. N., Nebbioso, A., Scognamiglio, A. & Gronemeyer, H. Acute myeloid leukemia: Therapeutic impact of epigenetic drugs. Int. J. Biochem. Cell Biol. 37, 1752-1762 (2005).
119. Mizuno, S. et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 97, 1172-1179 (2001).
120. Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587-596 (2004).
121. Chaffanet, M. et al. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 28, 138-144 (2000).
122. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005).
123. Fraga, M. F. et al. Loss of acetylation at Lys 16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391-400 (2005).
124. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
125. Shulman, A. I. & Mangelsdorf, D. J. Retinoid receptor heterodimer's in the metabolic syndrome. N. Engl J. Med. 353, 604-615 (2005).
126. Claudel, T. et al. Reduction of atherosclerosis in apolipoprotein E Knockout mice by activation of the retinoid X receptor. Proc. Natl Acad. Sci. US4 98, 2610-2615 (2001).
127. Desreumaux, P. et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193, 827-838 (2001).
128. Ferre, P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (Suppl. 1), 43-50 (2004).
129. Mukherjee, R. et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407-410 (1997).
130. Liu, S. et al. Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology 143 2880-2885 (2002).
131. Haffner, C. D. et al. Structure-based design of potent retinoid X receptor α agonists. J. Med. Chem. 47, 2010-2029 (2004).
132. Li. X., Hansen, P. A., Xi, L., Chandraratna, R. A. & Burant, C. F. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor γ and retinoic acid X receptors. J. Biol. Chem. 280, 38317-38327 (2005).
133. Ogilvie, K. M. et al. Activation of the retinoid X receptor suppresses appetite in the rat. Endocrinology 145, 565-573 (2004).
134. Singh Ahuja, H. et al. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol. Pharmacol. 59, 765-773 (2001).
135. Way, J. M. et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated recept γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142, 1269-1277 (2001).
136. Martin. G. et al. Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimerselective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target. J. Biol. Chem. 275, 12612-12618 (2000).
137. Shen. O., Cline, G. W., Shulman, G. I., Leibowitz, M. D. & Davies, P. J. Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice. J. Biol. Chem. 279. 19721-19731 (2004).
138. Yamauchi, T. et al. Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J. Clin. Invest. 108 1001-1013 (2001).
139. Leibowitz, M. D. et al. Biological characterization of a heterodimer-selective retinoid X receptor modulator: Potential benefits for the treatment of type 2 diabetes. Endocrinology 147, 1044-1053 (2006).
140. Haugen, B. R. et al. Retinoid X receptor γ-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet. Endocrinology 145, 3679-3685 (2004).
141. Brown, N. S. et al. Thyroid hormone resistance and increased metabolic rate in the RXR-γ-deficient mouse. J. Clin. Invest. 106, 73-79 (2000).
142. Ross, A. W. et al. Temporal changes in gene expression in the arcuate nucleus precede seasonal responses in adiposity and reproduction. Endocrinology 146, 1940-1947 (2005).
143. -/- mutant mice are viable. Proc. Natl Acad. Sci. USA 93, 9010-9014 (1996).
144. Imai, T., Jiang, M., Chambon, P. & Metzger, D. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor α mediated by a tamoxifen-inducible chimeric Cre recombinase, (Cre-ERT2) in adipocytes. Proc. Natl Acad. Sci. USA 98, 224-228 (2001).
145. Yotsumoto, T, Naitoh, T., Kanaki. T. & Tsuruzoe, N. A retinoid X receptor antagonist, HX531, improves leptin resistance without increasing plasma leptin level in KK-Ay mice under normal dietary conditions. Metabolism 54, 573-578 (2005).
146. Davies, P. J. et al. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol. Pharmacol. 59, 170-176 (2001).
147. Forman, B. M. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor γ ligands. J. Biol. Chem. 277, 12503-12506 (2002).
148. Deng, T. et al. A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice. Biol. Pharm. Bull. 28, 1192-1196 (2005).
149. Michellys, P Y. et al. Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methyloctal-2,4.6-trienoic acids. J. Med. Chem. 46, 4087-4103 (2003).
150. Cesario, R. M. et al. The rexinoid LG100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. Mol. Endocrinol. 15, 1360-1369 (2001).
151. Bennett, J. M. et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 103, 620-625 (1985).
152. Bennett, J. M. et al. Proposals for the classification of the acute leukaemias, French-American-British (FAB) co-operative group. Br. J. Haematol. 33, 451-458 (1976).
153. Pandolfi, P. P. et al. Genomic variability and alternative splicing generate multiple PML/RAR α transcripts that encode aberrant PML proteins and PML/RAR α isoforms in acute promyelocytic leukaemia. EMBO J. 11, 1397-1407 (1992).
154. Li, Y. P. et al. RAR α 1/RAR α2-PML mRNA expression in acute promyelocytic leukemia cells: A molecular and laboratory-clinical correlative study. Blood 90, 306-312 (1997).
155. Zhang, T. D. et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene 20, 7146-7153 (2001).
156. Slack, J. L & Gallagher, R. E. The molecular biology of acute promyelocytic leukemia. Cancer Treat. Res. 99, 75-124 (1999).
157. Piazza, F., Gurrieri, C. & Pandolfi, P. P. The theory of APL. Oncogene 20, 7216-7222 (2001).
158. Bianchi, L. et al. Topical treatment of basal cell carcinoma with tazarotene: A clinicopathological study on a large series of cases. Br J. Dermatol. 151, 148-156 (2004).
159. Gehin, M. et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem. Biol. 6, 519-529 (1999).
160. Beard, R. L. et al. Synthesis and biological activity of retinoic acid receptor-α specific amides. Bioorg. Med. Chem. Lett. 12 3145-3148 (2002).
161. Teng, M. et al. Identification of highly potent retinoic acid receptor α-selective antagonists. J. Med. Chem. 40, 2445-2451 (1997).
162. Ostrowski, J. et al. Serine 232 and methionine 272 define the ligand binding pocket in retinoic acid receptor subtypes. J. Biol. Chem. 273, 3490-3495 (1998).
163. Yu, K.-L et al. Structural modifications of 6-naphthalene-2-carboxylate retinoids Bioorg. Med. Chem. Lett. 6, 2865-2870 (1996).
164. Klaholz, B. P., Mitschler A. & Moras, D. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J. Mol. Biol. 302, 155-170 (2000).
165. Klaholz, B. P. et al. Conformational adaptation of agonists to the human nuclear receptor RAR γ. Nature Struct. Biol. 5, 199-202 (1998).
166. Klaholz, B. P., Mitschler, A., Belema, M., Zusi, C. & Moras, D. Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARγ. Proc. Natl Acad. Sci. 97, 6322-6327 (2000).
167. Charpentier, B. et al. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem. 38, 4993-5006 (1995).
168. Szondy, Z. et al. Induction of apoptosis by retinoids and retinoic acid receptor γ-selective compounds in mouse thymocytes through a novel apoptosis pathway. Mol. Pharmacol. 51, 972-982 (1997).
169. Zhang. L. et al. Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells. J. Med. Chem. 50, 2659-2663 (1996).
170. Dawson, M. I. et al. 4-[3-(5.6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl] phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor α agonists. Bioorg. Med. Chem. Lett. 10, 1311-1313 (2000)
171. Egea, P. F. et al. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J. 19, 2592-2601 (2000).
172. Korichneva, I. & Hammerling, U. F-actin as a functional target for retro-retinoids: A potential role in anhydroretinol-triggered cell death. J. Cell Sci. 112, 2521-2528 (1999).
173. Chen, Y., Buck, J. & Derguini, F. Anhydroretinol induces oxidative stress and cell death. Cancer Res. 59, 3985-3990 (1999).
174. Hoyos, B. et al. Activation of c-Raf kinase by ultraviolet light. Regulation by retinoids. J. Biol. Chem. 277, 23949-23957 (2002).
175. O'Connell, M. J. et al. Retro-retinoids in regulated cell growth and death. J. Exp. Med. 184, 549-555 (1996).
176. Buck, J. et al. Anhydroretinol: A naturally occurring inhibitor of lymphocyte physiology. J. Exp. Med. 178, 675-680 (1993).
177. Um, S.-J. et al. Novel retinoic acid derivative ABPN has potent inhibitory activity on cell growth and apoptosis in cancer cells. Int. J. Cancer 107, 1038-1046 (2003).
178. Kaufmann, F., Tanaka, T. & Tsukaguchi, T. Antiproliferative effects of the arotinoid Ro 40-8757 on human cancer cells in vitro. Br. J. Cancer 67, 1293-1298 (1993).
179. Simoni, D. et al. Programmed cell death (PCD) associated with the stilbene motif of arotinoids: Discovery of novel apoptotic inducer agents possessing activity on multidrug resistant tumor cells. Bioorg. Med. Chem. Lett. 10, 2669-2673 (2000).
180. Hsu, C.,A. et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 89, 4470-4479 (1997).
181. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11, 493-504 (1995).
182. Keedwell, R. G. et al. A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation. Cancer Res. 64, 3302-3312 (2004).
183. Farhana, L., Dawson, M. I. & Fontana. J. A. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-κB activation. Cancer Res. 65, 4909-4917 (2005).
184. Dawson, M. I. et al. Antagonist analogue of 6-[3′-(1-adamantyl)-4′-hydroxypheny]-2-naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest. J. Med. Chem. 47, 3618-3536 (2004).